ClinicalTrials.gg
RecruitingNCT05389293Updated Aug 10, 2026

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

A Phase 2 interventional study of Mosunetuzumab and Zanubrutinib in Follicular Lymphoma and Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
152
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing mosunetuzumab in Lymphoma, Follicular — 8 open to participants now, 15 under way, 3 of them phase 3. mosunetuzumab · Lymphoma, Follicular.

Planned enrollment
5th of 17
152 · median 42
Started
2022
with 5 others
Phase 2
11 of 17
7 open now
Primary completion
2027-12
later than 7 of 14 live
Registered
6th of 17
by date
Lead sponsor
1 of 17
Memorial Sloan Kettering Cancer Center

Among the 17 studies testing mosunetuzumab in Lymphoma, Follicular, this one is the 5th largest by planned enrollment, is one of 6 that started in 2022, is one of 11 in phase 2, reaches primary completion later than 7 of the 14 other live ones, and was the 6th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

8 of the 17 studies testing mosunetuzumab in Lymphoma, Follicular are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About mosunetuzumab

mosunetuzumab: first FDA approval 2022 (LUNSUMIO VELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing mosunetuzumab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.

Read the detailed description

After completing enrollment of the initial 53 subjects, the researchers plan to expand the study by an additional 23 subjects.

03

Conditions studied

  • Follicular Lymphoma
  • Lymphoma

Keywords

  • Mosunetuzumab
  • Follicular Lymphoma
  • Lymphoma
  • Memorial Sloan Kettering Cancer Center
  • 22-100
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Form(s)
  • Ability to comply with all the study-related procedures, in the investigator's judgement
  • Age 18 years or older
  • performance Status of 0, 1, or 2 [Appendix 2]
  • Untreated documented FL of grade 1, 2, or 3A
  • Stage II bulky (noncontiguous), III, or IV bulky or high burden disease [Appendix 3]
  • Need of systemic therapy as evidenced by at least one of the following criteria [also see Appendix 4]:

    • Bulky disease defined as:
    • Nodal or extranodal mass > 7cm in maximum diameter
    • ≥ 3 nodal or extranodal sites each with a diameter ≥ 3 cm
    • Presence of any of the following constitutional symptoms:
    • Fever (>38C) of unclear etiology
    • Night sweats
    • Weight loss >10% within the prior 6 months
    • Symptomatic splenomegaly
    • Mass-related symptoms
    • End-organ damage (e.g., elevated creatinine or elevated liver enzymes) that is clearly related to lymphomatous infiltration in the opinion of the investigator
    • Any one of the following cytopenias due to lymphoma:
    • \< 10g/dL
    • \<100 x 10\^9/L
    • (ANC) \< 1.5 x 10\^9/L
    • Pleural or peritoneal serous effusion (irrespective of cell content)
    • Patients with absolute lymphocytosis ≥5,000 cells/µL in the peripheral blood may be allowed to participate after discussion with the study PI
  • Must be considered as a potential candidate for chemoimmunotherapy in the judgement of the treating physician
  • Must have at least one bi-dimensionally (>1.5 cm in its largest dimension for nodal lesions, or >1.0 cm in its largest dimension for extranodal lesions by computerized tomography [CT] scan or MRI)
  • Agreement to provide tumor samples as follows:

    • Agreement to undergo of a safely accessible tumor site per investigator determination prior to the first dose of mosunetuzumab.
    • Agreement to undergo repeat biopsy of the same tumor site, if safely accessible, or a different safely accessible tumor site, per investigator determination, 14 to 21 days after the first dose of mosunetuzumab.
    • Patients who are unable or unwilling to undergo either biopsy procedure may be allowed to participate in, or continue with, the study without any penalization after confirmation from the PI. Inability to undergo a new pre-treatment or an on-treatment biopsy are not considered protocol violations.
  • Adequate hepatic function as follows: (AST) and alanine transaminase (ALT) levels ≤3 x (ULN); total level ≤1.5 x ULN (except with documented history of Gilbert syndrome)
  • Adequate bone marrow function as follows:

    • Platelet count ≥75 x 10\^9/L without transfusion within 14 days prior to first dose of mosunetuzumab;
    • ANC ≥1 x 10\^9/L
    • Hemoglobin level ≥9 g/dL without transfusion within 14 days prior to the first dose of mosunetuzumab
    • Patients who do not meet criteria for bone marrow function due to marrow involvement of lymphoma and/or other disease-related cytopenias (e.g., immune thrombocytopenia) may be enrolled into the study after discussion with, and confirmation by the PI.
  • Serum creatinine ≤ULN or estimated ≥ 45 mL/min by Cockcroft-Gault method [see Appendix 5] or other institutional standard methods (e.g., based on nuclear medicine renal scan)
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of ≤1% per year, and agreement to refrain from donating eggs, during the treatment period and for at least 3 months after the last dose of mosunetuzumab, and 3 months after the last dose of tocilizumab (if applicable), whichever is longer.

    • A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
    • Examples of contraceptive methods with a failure rate of ≤1% per year include bilateral tubal ligation, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.Hormonal contraception methods must be supplemented by a barrier method.
    • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse), or use a condom, and agreement to refrain from donating sperm, as defined below:

    • With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 60 days after the last dose of mosunetuzumab and tocilizumab (if applicable) to avoid exposing the embryo. Men must refrain from donating sperm during this same period.
    • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence and withdrawal are not acceptable methods of contraception.

Exclusion criteria

Exclusion Criteria:

  • Inability to comply with all the study-related procedures, in the investigator's judgement.
  • FL grade 3B or transformed FL
  • Patients not meeting criteria for systemic therapy as outlined in section 6.1 and Appendix 4
  • Patients unfit for chemoimmunotherapy for reasons including, but not limited to, advanced age and medical comorbidities
  • FL presenting with isolated extra-nodal localizations, such as duodenal FL, cutaneous FL or FL of the testis
  • Pediatric FL
  • Prior anti-lymphoma therapy
  • Prior solid organ transplantation
  • Prior stem cell transplantation within 5 years of FL diagnosis. Previously transplanted patients must be off all -related prophylaxis in order to be considered eligible.
  • Current or prior central nervous system (CNS) lymphoma
  • Current or past history of significant CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease

    • Patients with a history of stroke who have not experienced a stroke or in the past 2 years and have no residual neurologic deficits as judged by the investigator are allowed
    • Patients with a history of epilepsy who have had no seizures in the past 2 years while not receiving any anti-epileptic medications are allowed
  • Significant cardiovascular disease such as Class III or IV cardiac disease [see Appendix 6], myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina
  • Significant active pulmonary disease (e.g., bronchospasm or obstructive pulmonary disease)
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to first mosunetuzumab administration
  • Known or suspected chronic active Epstein-Barr Virus infection
  • Serologic or PCR test results indicating acute or chronic infection

    ° Patients whose HBV infection status cannot be determined by serologic test results (www.cdc.gov/hepatitis/hbv/pdfs/serologicchartv8.pdf) must be negative for HBV by PCR to be eligible for study participation.

  • Acute or chronic infection

    ° Patients who are positive for HCV antibody must be negative for HCV by PCR to be eligible for study participation.

  • Serologic test results indicating infection
  • Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a will be required during the study

    • Patients must not receive live, attenuated vaccines (e.g., FluMist®) while receiving study treatment or after the last dose until B-cell recovery to the normal ranges. Killed vaccines or toxoids should be given at least 4 weeks prior to the first dose of study treatment to allow development of sufficient immunity.
    • Inactivated influenza vaccination during influenza season and the COVID-19 vaccination at any time are allowed. Please see section 10.3.2 (permitted concomitant therapy) for additional guidance on SARS-CoV-2 vaccine administration and timing
    • Investigators should review the vaccination status of potential study patients being considered for this study and follow the U.S. Centers for Disease Control and Prevention guidelines for adult vaccination with any other non-live vaccines intended to prevent infectious diseases prior to study.
  • Pregnant, lactating, or intending to become pregnant during the study or within 3 months after the last dose of mosunetuzumab and 3 months after the last dose of tocilizumab (if applicable)

    ° Women who are not (≥12 months of non-therapy-induced amenorrhea) or surgically sterile (removal of ovaries and/or uterus) must have a negative serum pregnancy test result within 14 days prior to initiation of study drug. If a serum pregnancy test has not been performed within 14 days prior to receiving first study treatment, a negative urine pregnancy test result (performed within 7 days prior to study treatment) must be available.

  • Radiation therapy, unless utilized for the sole purpose of acutely controlling symptomatic disease during the screening period. In this case, at least 2 weeks should lapse between the last radiation dose and the first mosunetuzumab administration and the patient must still have outside the field of radiation prior to initiation of the study drug
  • Recent major surgery within 4 weeks prior to first mosunetuzumab administration, except protocol-mandated procedures (e.g., tumor and bone marrow biopsies)
  • History of disease, including, but not limited to myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis

    • Patients with a remote history of, or well-controlled autoimmune disease, may be eligible to enroll after discussion with and confirmation by the PI.
    • Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
    • Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study.
    • Patients with a history of disease-related immune thrombocytopenic purpura or autoimmune hemolytic anemia may be eligible for this study.
    • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
    • Rash must cover \<10% of body surface area
    • Disease is well controlled at baseline and requires only low-potency topical
    • No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous 12 months.
  • History of known HLH or suspected HLH in the opinion of the investigator
  • History of confirmed progressive multifocal leukoencephalopathy (PML)
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
  • History of other , except:

    • Curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, in situ cervical carcinoma, in situ prostatic neoplasia.
    • A malignancy treated with curative intent and in remission for at least 2 years prior to the first mosunetuzumab administration
  • Receipt of systemic medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) with the exception of corticosteroid treatment ≤10 mg/day prednisone or equivalent within 2 weeks prior to first dose of mosunetuzumab. The following is permitted:

    • The use of up to 12 mg/day dexamethasone for up to 3 days as antiemetic therapy
    • The use of up to 1mg/kg of prednisone or equivalent for ≤7 days to control B symptoms
    • The use of inhaled corticosteroids
    • The use of mineralocorticoids for management of orthostatic hypotension
    • The use of physiologic doses of corticosteroids for management of adrenal insufficiency
    • The use of premedication corticosteroids prior to undergoing contrast-enhanced imaging studies, in patients who are allergic to contrast agents
  • History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's or PI's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results

Cohort 2 only:

  • Requirement fors ongoing treatment with a strong inhibitor or inducer (see section 15.2.3.2)
  • History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention.
  • History of intracranial hemorrhage ≤ 180 days before the first dose of study treatment
  • Inability to swallow capsules or gastrointestinal dysfunction such as demonstrated malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery, symptomatic inflammatory bowel disease, or bowel obstruction.
  • Consumption of one or more of the following within 3 days prior to the first dose of zanubrutinib:

    • Grapefruit or grapefruit products
    • Seville oranges, including marmalade containing Seville oranges
    • Star fruit (carambola)
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Single Agent Mosunetuzumab

    Participants with newly diagnosed FL in need of systemic therapy

    Drug: Mosunetuzumab

  • Experimental
    Mosunetuzumab + Zanubrutinib

    Participants with newly diagnosed FL in need of systemic therapy

    Drug: Mosunetuzumab · Drug: Zanubrutinib

Interventions

  • During Cycle 1, Mosunetuzumab will be administered SC in a step-up dosing schedule at the dose of 5 mg on Day 1, 45 mg on Day 8, and 45 mg on Day 15). Beginning with Cycle 2, Mosunetuzumab will be administered SC at the dose of 45 mg on Day 1. Each Cycle lasts 3 weeks. After the first 8 cycles (approximately 6 months) of therapy, subjects who achieved CR will discontinue therapy, those who attained a PR will receive up to 17 doses (approximately 12 months). Subjects who achieve stable disease (SD) or who experience progressive disease (PD) will be taken off study and subsequent management will be left at the discretion of the investigator.

  • In Cohort 2, Zanubrutinib is concurrently administered continuously starting on Cycle 1, Day -7 and is given for 12 months in both patients with CR and those with PR. Cohort 2 patients with evidence of circulating lymphoma cells at baseline will initiate Zanubrutinib dosing on Cycle 2 Day 1 and continue dosing for 12 months.

06

What researchers measure

Primary outcomes

  1. Rate of Complete Respons/CR

    The primary objective of the study is to determine the rate of Complete Response/CR to single-agent SC mosunetuzumab according to the 2014 Lugano response criteria in participants with newly diagnosed Follicular Lymphoma in need of systemic therapy.

    Time frame: Up to 1 year

Secondary outcomes

  1. Overall Response Rate/ORR

    Assess the Overall Response Rate/ORR after treatment with single-agent SC mosunetuzumab mosunetuzumab

    Time frame: Up to 3 years

07

Study locations

9 of 9 sites recruiting
  • Georgetown University (Data Collection Only)
    Washington D.C., District of Columbia 20007, United States
    Recruiting
    • Joseph Roswarski, MD · Contact(202) 444-2223
  • Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Lorenzo Falchi, MD · Contact646-608-3705
  • Hackensack Meridian Health (Data collection only)
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Lori Leslie, MD · Contact(551) 996-3033
  • Memorial Sloan Kettering Monmouth (Limited protocol activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Lorenzo Falchi, MD · Contact646-608-3705
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Lorenzo Falchi, MD · Contact646-608-3705
  • Memorial Sloan Kettering Suffolk- Commack (Limited protocol activities)
    Commack, New York 11725, United States
    Recruiting
    • Lorenzo Falchi, MD · Contact646-608-3705
  • Memorial Sloan Kettering Westchester (Limited protocol activities)
    Harrison, New York 10604, United States
    Recruiting
    • Lorenzo Falchi, MD · Contact646-608-3705
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
  • Memorial Sloan Kettering Nassau (Limited protocol activities)
    Rockville Centre, New York 11553, United States
    Recruiting
    • Lorenzo Falchi, MD · Contact646-608-3705
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2027, 67 months after the start.

Of 151 non-industry phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 110. This study's planned 67 months is close to that.

Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
May 25, 2022
StartActual
May 27, 2022
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05389293
Responsible party
Sponsor
First posted
May 25, 2022
Start date
May 27, 2022
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

Lorenzo Falchi, MD
Contact
FalchiL@mskcc.org
646-608-3705
Gilles Salles, MD, PhD
Contact
SallesG@mskcc.org
646-608-4153
Lorenzo Falchi, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mosunetuzumab

Start the discussion